Finally, the CDKN2A/B locus appears to be involved in the progression of CML, and JAK2 could play a role in TKI resistance through a BCR-ABL1/JAK2 network [39,40]. This evidence concerns the gene JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive.